SMS Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 4/6
De winst van SMS Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -4.9%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 13.3%. De inkomsten zijn groeide met een gemiddeld percentage van 9.6% per jaar. Het rendement op het eigen vermogen SMS Pharmaceuticals bedraagt 10.5% en de nettomarge bedraagt 7.7%.
Belangrijke informatie
-4.9%
Groei van de winst
-5.0%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 17.5% |
Inkomstengroei | 9.6% |
Rendement op eigen vermogen | 10.5% |
Nettomarge | 7.7% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18Opbrengsten en kosten
Hoe SMS Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 7,685 | 593 | 716 | 0 |
30 Jun 24 | 7,384 | 570 | 666 | 0 |
31 Mar 24 | 7,093 | 498 | 658 | 0 |
31 Dec 23 | 6,129 | 361 | 615 | 0 |
30 Sep 23 | 6,002 | 288 | 598 | 0 |
30 Jun 23 | 5,930 | 150 | 571 | 0 |
31 Mar 23 | 5,221 | -71 | 548 | 0 |
31 Dec 22 | 4,335 | -42 | 535 | 0 |
30 Sep 22 | 4,060 | 9 | 532 | 0 |
30 Jun 22 | 4,211 | 259 | 517 | 0 |
31 Mar 22 | 5,199 | 622 | 515 | 0 |
31 Dec 21 | 6,348 | 789 | 499 | 0 |
30 Sep 21 | 6,612 | 911 | 475 | 0 |
30 Jun 21 | 6,172 | 791 | 442 | 0 |
31 Mar 21 | 5,632 | 625 | 415 | 0 |
31 Dec 20 | 4,911 | 458 | 405 | 0 |
30 Sep 20 | 4,226 | 319 | 398 | 0 |
30 Jun 20 | 4,130 | 308 | 386 | 0 |
31 Mar 20 | 4,143 | 316 | 410 | 0 |
31 Dec 19 | 4,206 | 386 | 398 | 0 |
30 Sep 19 | 4,412 | 405 | 389 | 0 |
30 Jun 19 | 4,606 | 406 | 366 | 0 |
31 Mar 19 | 4,667 | 400 | 372 | 0 |
31 Mar 18 | 4,639 | 317 | 343 | 0 |
31 Mar 17 | 4,388 | 285 | 288 | 0 |
31 Mar 16 | 6,032 | 409 | 406 | 0 |
31 Dec 15 | 5,902 | 391 | 579 | 0 |
30 Sep 15 | 5,828 | 396 | 566 | 0 |
30 Jun 15 | 5,651 | 343 | 330 | 0 |
31 Mar 15 | 5,793 | 352 | 533 | 0 |
31 Dec 14 | 5,730 | 358 | 504 | 0 |
30 Sep 14 | 5,624 | 327 | 493 | 0 |
30 Jun 14 | 5,567 | 326 | 282 | 0 |
31 Mar 14 | 5,180 | 204 | 455 | 0 |
31 Dec 13 | 3,976 | 686 | 372 | 0 |
Kwaliteitswinsten: SMSPHARMA heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (7.7%) SMSPHARMA } zijn hoger dan vorig jaar (4.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van SMSPHARMA is de afgelopen 5 jaar met 4.9% per jaar gedaald.
Versnelling van de groei: De winstgroei van SMSPHARMA over het afgelopen jaar ( 106.2% ) overtreft het 5-jarig gemiddelde ( -4.9% per jaar).
Winst versus industrie: De winstgroei SMSPHARMA over het afgelopen jaar ( 106.2% ) overtrof de Pharmaceuticals -sector 20.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 10.5% ) van SMSPHARMA wordt als laag beschouwd.